Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Apr, 2015 | Pages:
74 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Vertex Pharmaceuticals Incorporated - Product Pipeline Review - 2015 Summary Global Markets Direct's, 'Vertex Pharmaceuticals Incorporated - Product Pipeline Review - 2015', provides an overview of the Vertex Pharmaceuticals Incorporated's pharmaceutical research and development focus. This report provides comprehensive information on the current therapeutic developmental pipeline of Vertex Pharmaceuticals Incorporated's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides brief overview of Vertex Pharmaceuticals Incorporated including business description, key information and facts, and its locations and subsidiaries - The report reviews current pipeline of Vertex Pharmaceuticals Incorporated's human therapeutic division and enlists all their major and minor projects - The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones - Special feature on out-licensed and partnered product portfolio - The report summarizes all the dormant and discontinued pipeline projects - Latest company statement - Latest news and deals relating to the Vertex Pharmaceuticals Incorporated's pipeline products Reason To Buy - Evaluate Vertex Pharmaceuticals Incorporated's strategic position with total access to detailed information on its product pipeline - Assess the growth potential of Vertex Pharmaceuticals Incorporated in its therapy areas of focus - Identify new drug targets and therapeutic classes in the Vertex Pharmaceuticals Incorporated's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas - Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps - Develop strategic initiatives by understanding the focus areas of Vertex Pharmaceuticals Incorporated and exploit collaboration and partnership opportunities - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Plan mergers and acquisitions effectively by identifying the most promising pipeline of Vertex Pharmaceuticals Incorporated - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Explore the dormant and discontinued projects of Vertex Pharmaceuticals Incorporated and identify potential opportunities in those areas - Avoid Intellectual Property Rights related issues
Table of Contents
Table of Contents 2 List of Tables 5 List of Figures 5 Vertex Pharmaceuticals Incorporated Snapshot 6 Vertex Pharmaceuticals Incorporated Overview 6 Key Information 6 Key Facts 6 Vertex Pharmaceuticals Incorporated - Research and Development Overview 7 Key Therapeutic Areas 7 Vertex Pharmaceuticals Incorporated - Pipeline Review 10 Pipeline Products by Stage of Development 10 Pipeline Products - Monotherapy 11 Pipeline Products - Combination Treatment Modalities 12 Pipeline Products - Out-Licensed Products 13 Out-Licensed Products/Combination Treatment Modalities 14 Vertex Pharmaceuticals Incorporated - Pipeline Products Glance 15 Vertex Pharmaceuticals Incorporated - Late Stage Pipeline Products 15 Pre-Registration Products/Combination Treatment Modalities 15 Phase III Products/Combination Treatment Modalities 16 Vertex Pharmaceuticals Incorporated - Clinical Stage Pipeline Products 17 Phase II Products/Combination Treatment Modalities 17 Phase I Products/Combination Treatment Modalities 18 Vertex Pharmaceuticals Incorporated - Early Stage Pipeline Products 19 Preclinical Products/Combination Treatment Modalities 19 Discovery Products/Combination Treatment Modalities 20 Vertex Pharmaceuticals Incorporated - Drug Profiles 21 (lumacaftor + ivacaftor) 21 Product Description 21 Mechanism of Action 21 R&D Progress 21 (VX-661 + ivacaftor) 24 Product Description 24 Mechanism of Action 24 R&D Progress 24 decernotinib 26 Product Description 26 Mechanism of Action 26 R&D Progress 26 VX-210 27 Product Description 27 Mechanism of Action 27 R&D Progress 27 VX-970 30 Product Description 30 Mechanism of Action 30 R&D Progress 30 telaprevir 31 Product Description 31 Mechanism of Action 31 R&D Progress 31 VX-803 35 Product Description 35 Mechanism of Action 35 R&D Progress 35 Small Molecule to Inhibit HSP90 alpha/beta for Huntington's Disease 36 Product Description 36 Mechanism of Action 36 R&D Progress 36 Small Molecules to Inhibit Protein Kinase for Tuberculosis 37 Product Description 37 Mechanism of Action 37 R&D Progress 37 VE-465 39 Product Description 39 Mechanism of Action 39 R&D Progress 39 VE-821 40 Product Description 40 Mechanism of Action 40 R&D Progress 40 VE-822 41 Product Description 41 Mechanism of Action 41 R&D Progress 41 VXc-486 42 Product Description 42 Mechanism of Action 42 R&D Progress 42 Next Generation Correctors 43 Product Description 43 Mechanism of Action 43 R&D Progress 43 Small Molecule to Antagonize CGRP Receptor for Migraine 45 Product Description 45 Mechanism of Action 45 R&D Progress 45 Small Molecule to Inhibit PI3K Gamma for Undisclosed Indications 46 Product Description 46 Mechanism of Action 46 R&D Progress 46 Small Molecules for Cancer 47 Product Description 47 Mechanism of Action 47 R&D Progress 47 Small Molecules for Multiple Sclerosis 48 Product Description 48 Mechanism of Action 48 R&D Progress 48 VT-12008911 49 Product Description 49 Mechanism of Action 49 R&D Progress 49 Vertex Pharmaceuticals Incorporated - Pipeline Analysis 50 Vertex Pharmaceuticals Incorporated - Pipeline Products by Target 50 Vertex Pharmaceuticals Incorporated - Pipeline Products by Route of Administration 52 Vertex Pharmaceuticals Incorporated - Pipeline Products by Molecule Type 53 Vertex Pharmaceuticals Incorporated - Pipeline Products by Mechanism of Action 54 Vertex Pharmaceuticals Incorporated - Recent Pipeline Updates 55 Vertex Pharmaceuticals Incorporated - Dormant Projects 63 Vertex Pharmaceuticals Incorporated - Discontinued Pipeline Products 64 Discontinued Pipeline Product Profiles 64 ALS-2158 64 pralnacasan 64 VX-745 64 VX-759 64 VX-983 65 Vertex Pharmaceuticals Incorporated - Company Statement 66 Vertex Pharmaceuticals Incorporated - Locations And Subsidiaries 71 Head Office 71 Other Locations & Subsidiaries 71 Appendix 73 Methodology 73 Coverage 73 Secondary Research 73 Primary Research 73 Expert Panel Validation 73 Contact Us 73 Disclaimer 74
List of Tables
Vertex Pharmaceuticals Incorporated, Key Information 6 Vertex Pharmaceuticals Incorporated, Key Facts 6 Vertex Pharmaceuticals Incorporated - Pipeline by Indication, 2015 9 Vertex Pharmaceuticals Incorporated - Pipeline by Stage of Development, 2015 10 Vertex Pharmaceuticals Incorporated - Monotherapy Products in Pipeline, 2015 11 Vertex Pharmaceuticals Incorporated - Combination Treatment Modalities in Pipeline, 2015 12 Vertex Pharmaceuticals Incorporated - Out-Licensed Products in Pipeline, 2015 13 Vertex Pharmaceuticals Incorporated - Out-Licensed Products/ Combination Treatment Modalities, 2015 14 Vertex Pharmaceuticals Incorporated - Pre-Registration, 2015 15 Vertex Pharmaceuticals Incorporated - Phase III, 2015 16 Vertex Pharmaceuticals Incorporated - Phase II, 2015 17 Vertex Pharmaceuticals Incorporated - Phase I, 2015 18 Vertex Pharmaceuticals Incorporated - Preclinical, 2015 19 Vertex Pharmaceuticals Incorporated - Discovery, 2015 20 Vertex Pharmaceuticals Incorporated - Pipeline by Target, 2015 51 Vertex Pharmaceuticals Incorporated - Pipeline by Route of Administration, 2015 52 Vertex Pharmaceuticals Incorporated - Pipeline by Molecule Type, 2015 53 Vertex Pharmaceuticals Incorporated - Pipeline Products by Mechanism of Action, 2015 54 Vertex Pharmaceuticals Incorporated - Recent Pipeline Updates, 2015 55 Vertex Pharmaceuticals Incorporated - Dormant Developmental Projects,2015 63 Vertex Pharmaceuticals Incorporated - Discontinued Pipeline Products, 2015 64 Vertex Pharmaceuticals Incorporated, Other Locations 71 Vertex Pharmaceuticals Incorporated, Subsidiaries 72
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
